Foghorn Therapeutics announced its Q3 2025 financial results today, reporting a loss for the quarter while beating revenue estimates. The company also disclosed that Chief Financial Officer Kristian Humer will depart the organization.
The update highlighted a strong balance sheet, with $180.3 million in cash, cash equivalents, and marketable securities as of September 30 2025, providing a runway into 2028. Program updates included the ongoing Phase 1 dose‑escalation trial of FHD‑909 in SMARCA4‑mutated cancers, the entry of the selective CBP degrader into non‑GLP toxicology studies, and progress on the selective EP300 and ARID1B degrader programs.
These developments underscore Foghorn’s continued focus on its Gene Traffic Control platform and its partnership with Eli Lilly. The CFO transition and robust cash position position the company to sustain its pipeline development and maintain momentum in advancing its precision oncology candidates.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.